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Abstract
Background: Animal models of ADHD suggest that the paradoxical calming effect of methylphenidate on motor 
activity could be mediated through its action on serotonin transmission. In this study, we have investigated the 
relationship between the 5-HTTLPR polymorphism in the serotonin transporter gene (SLC6A4) and the response of 
ADHD relevant behaviors with methylphenidate treatment.
Methods: Patients between ages 6-12 (n = 157) were assessed with regard to their behavioral response to 
methylphenidate (0.5 mg/kg/day) using a 2-week prospective within-subject, placebo-controlled (crossover) trial. The 
children were then genotyped with regard to the triallelic 5-HTTLPR polymorphism in the SLC6A4 gene. Main outcome 
measure: Conners' Global Index for parents (CGI-Parents) and teachers (CGI-Teachers) at baseline and at the end of each 
week of treatment with placebo and methylphenidate. For both outcome measurements, we used a mixed model 
analysis of variance to determine gene, treatment and gene × treatment interaction effects.
Results: Mixed model analysis of variance revealed a gene × treatment interaction for CGI-Parents but not for CGI-
Teachers. Children homozygous for the lower expressing alleles (s+lG = s') responded well to placebo and did not derive 
additional improvement with methylphenidate compared to children carrying a higher expressing allele (lA). No 
genotype main effects on either CGI-Parents or CGI-teachers were observed.
Conclusions: A double blind placebo-controlled design was used to assess the behavioral effects of methylphenidate 
in relation to the triallelic 5-HTTLPR polymorphism of the SLC6A4 gene in children with ADHD. This polymorphism 
appears to modulate the behavioral response to methylphenidate in children with ADHD as assessed in the home 
environment by parents. Further investigation is needed to assess the clinical implications of this finding.
Trial Registration: ClinicalTrials.gov NCT00483106
Background
Attention-deficit/hyperactivity disorder (ADHD) is the
most common neurodevelopmental disorder in child-
hood, affecting 8-12% of children worldwide [1]. It is
characterized by developmentally inappropriate levels of
attention, motor activity and impulsivity. ADHD is char-
acterized by high heritability (0.76) [1], likely conferred
by several genes, each making a small contribution to the
overall risk for the disorder [1].
It has become common practice in genetic association
studies of ADHD to focus on genes implicated in brain
monoamine transmission, given that psychostimulant
drugs, such as methylphenidate (MPH), are effective in
controlling ADHD symptoms. It is widely believed that
this effect results primarily, but not exclusively, from
modulation of dopamine transmission and downstream
monoamine systems. Although this strategy of using a
"pharmacological bridge" to select candidate genes is rea-
sonable, it is possible that molecular mechanisms respon-
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underlying pathological processes of ADHD do not coin-
cide or coincide only to some extent. Numerous genetic
association studies investigating these pharmacological
candidates in relation to ADHD have been published.
However, results have proven difficult to replicate and the
odds ratios associated with each gene were low, ranging
from 1.13 to 1.45 (for review see [2]). This may reflect,
among other things, the low a priori probability that
these genes are implicated in ADHD [3]. In contrast, the
a priori probability that some of these genes are associ-
ated with the "drug response phenotype" may be substan-
tially higher given the important biological evidence that
psychostimulants interact with different molecular tar-
gets in the brain dopamine system and downstream neu-
rotransmission pathways. For example, it has been
demonstrated that MPH binds to the dopamine trans-
porter and blocks its activity [4]. Thus, genetic variants
that affect the structure and/or the function of the dop-
amine transporter may retain reasonable a priori proba-
bility to modulate behavioral response to MPH. In fact, in
a recent study [5], we found that the 3'-UTR VNTR poly-
morphism in the dopamine transporter gene modulates
behavioral response to MPH, replicating a previous study
by Stein et al. [6]. Additionally, investigating the "drug
response" phenotype has the important advantage of
being amenable to the placebo-controlled, double blind
study design, a robust design for controlling bias in
behavioral research studies.
Although the primary mechanism of action of MPH is
believed to involve increased synaptic dopamine and nor-
epinephrine levels, it has been suggested that behavioral
response to MPH may also be mediated through seroton-
ergic mechanisms acting downstream of the dopamine
system. Giros et al. have shown that dopamine trans-
porter gene-knockout mice display a high level of motor
activity, a phenotype amplified by exposure to a novel
environment [7]. This hyperactivity is reduced with the
administration of MPH, even though these animals dis-
play high levels of extra-cellular dopamine. Gainetdinov
et al. postulated that this paradoxical effect could be
mediated by serotonin (5-HT) neurotransmission path-
ways [8,9]. In accordance with this hypothesis, they have
shown that a selective 5-HT transporter inhibitor (fluox-
etine) or 5-HT enhancers (5-hydroxytryptophan or L-
tryptophan) significantly reduce motor hyperactivity in
this animal model but not in wild type animals. In con-
trast, in the same animal model, it was shown that nisoxi-
tine, a norepinephrine transporter blocker, does not
affect locomotor hyperactivity. Thus, it appears that the
level of dopaminergic tone may determine the potency of
the serotonergic enhancers in decreasing the hyperactiv-
ity observed in the dopamine transporter knockout
model of ADHD. Notwithstanding some problems in
extending these animal findings to children affected with
ADHD [10,11], these observations suggest that brain 5-
HT pathways may play a role in mediating the pharmaco-
logical effect of psychostimulants. Given the critical role
of the serotonin transporter (5-HTT) in regulation of 5-
HT transmission [12], the 5-HTT gene (SLC6A4) may be
considered a suitable candidate gene to explain at least
part of the variability in behavioral response to MPH.
A polymorphism in the promoter region of the sero-
tonin transporter gene (5-HTTLPR or 5-HTT gene-
linked polymorphic region) has been shown to modulate
transcriptional activity and availability of 5-HTT both in
vitro and in vivo with the short allele (s) having reduced
transcriptional activity compared to the long allele (l) [12-
14]. This polymorphism has been extensively studied in
relation to mood/anxiety disorders and impulse dyscon-
trol related disorders. It is generally believed that the s
allele (or the ss genotype), associated with low levels of
transcription of the SLC6A4, results in a desensitization
of post synaptic 5-HT receptors, which in turn increase
the risk for these disorders. More recently, it has been
shown that this polymorphism is triallelic, with the l
allele having two forms, lG and lA, resulting from a com-
mon GTA polymorphism. The lG allele creates a func-
tional AP2 transcription-factor binding site. Expression
assays showed nearly equivalent expression for the s and
lG alleles, accounting for more variation in 5-HTT expres-
sion [15]. Previous association studies between ADHD
and the 5-HTTLPR polymorphism yielded various results
[16-22]. Five case-control association studies reported an
association between 5-HTTLPR and ADHD or its symp-
tomatic dimensions [23-27]. These studies suggest that
the l allele may be associated with externalizing disorders
whereas the s allele may be related to internalization
symptoms. In line with these case-control studies, three
family studies reported a trend towards [16,18,21] and
one study reported a significant over transmission [17] of
the l allele of 5-HTTLPR from parents to children with
ADHD. The overall risk associated with SLC6A4 was esti-
mated to be 1.31 with 95% confidence interval of (1.09-
1.59) [2].
Under the assumption that 5-HT transmission may be
part of the biological mechanisms mediating behavioral
response to MPH, we have examined the association of
the polymorphic 5-HTTLPR with behavioral response to
MPH by using a double-blind, placebo-controlled cross-
over study to test this association.
Methods
Subjects
One hundred and fifty seven children were recruited
from the Disruptive Behavior Disorders Program and the
child psychiatry outpatient clinics at the Douglas Insti-
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care facilities by schools, community social workers, fam-
ily doctors and pediatricians.
To be included in the study, children had to be between
6 and 12 years of age and meet DSM-IV diagnostic crite-
ria for ADHD [28]. Diagnosis was based on observation
of the child's behavior and an interview with at least one
parent by a child psychiatrist. This clinical examination
was supplemented by a structured clinical interview of
parents using the DISC-IV (parental report) [29] as well
as school reports. In the majority of cases, mothers were
the primary informants. Parents completed the Child
Behavioral Checklist or CBCL [30], a scale that assesses
several behavioral domains of the child. For this scale,
parents were asked to give an overall evaluation of the
child's behavior without a specific timeframe.
In order to assess behavioral response to MPH, we used
the Conners' Global Index for parents (CGI-Parents) and
teachers (CGI-Teachers) [31]. Parents and teachers were
instructed to assess the child's behavior during the week
preceding each assessment. The CGI-Parents and CGI-
Teachers are subsets of the original Conners' Rating
Scales, widely used for assessing symptoms of ADHD and
other psychopathology in children between 3 and 17
years of age for which normative data have been well
established [32]. Each Conners' Global Index (CGI) scale
consists of 10 items representing the Hyperactivity Index
of the original Conners' scale. Each item describes a
behavior that is rated on a 4-point Likert scale from 0
(not at all true) to 3 (very true). CGI-Parents and CGI-
Teachers are each comprised of two factors: "Emotional
lability" and "Restless-impulsive behavior". The raw total
and factor scores are transformed into normalized T-
scores, with 65 or higher considered to be clinically sig-
nificant. This rating scale has been recommended for
titrating and monitoring treatment with psychostimulant
drugs [32]. All these assessments were completed during
the week preceding the clinical trial (i.e. at baseline) while
the children were not taking any medication.
Children with a history of Tourette's syndrome, bipolar
disorder, pervasive developmental disorder, psychosis or
any medical condition or impairment that would inter-
fere with the ability of the child to complete the study,
were excluded.
Procedure
Once each child completed the baseline evaluations, a 2-
week double-blind, placebo-controlled, within-subject
crossover experimental design was used to assess the
behavioral response to MPH as compared to placebo.
Since the primary purpose of the study was to investigate
the effect of the SLC6A4 genotype on the variability of
behavioral response to MPH, we used a moderate dose
(0.5 mg/kg/day) of MPH that has been shown to produce
a robust behavioral response in most children [33]. This
dose also follows the recommendations of initiating treat-
ment with MPH at a low to moderate dose and titrating
to higher doses if the child does not respond adequately
[34]. In addition, although several studies reported a lin-
ear dose-response curve of behaviors to MPH [35,36],
other studies suggested a curvilinear dose-response
curve, with higher doses adding only a marginal effect
compared to medium doses [37]. Thus, we reasoned that
using a 0.5 mg/kg/day is an adequate dose to study behav-
ioral response to MPH within its linear dose-response
curve segment. After one week of baseline assessments,
which also served as a wash-out period for children pre-
viously treated with MPH, subjects received one week of
treatment with placebo followed by one week of treat-
ment with 0.5 mg/kg/day of MPH given in a divided dose
(morning and noon). The order of administration (pla-
cebo and MPH) was blind, counterbalanced and deter-
mined by random assignment.
Placebo and MPH were prepared individually in
opaque gelatin capsules in weekly blister packs by a phar-
macist not otherwise involved in the study to maintain
the blind allocation of treatment. At the end of each week
of treatment, the blister packs were collected and medi-
cation compliance checked. At this time, a research assis-
tant contacted the child's parents and teacher and asked
them to fill the CGI-Parents and CGI-Teachers respec-
tively, taking into consideration the behavior of the child
during the entire previous week of treatment (including
weekends for parents).
The research protocol was approved by the Research
Ethics Board of the Douglas Institute. Parents provided
written informed consent. The study was explained to the
children and they gave their verbal assent to participate.
Molecular genetics
The 5-HTTLPR polymorphism of the SLC6A4 gene was
genotyped using PCR amplification of DNA and resolu-
tion of different alleles using agarose gel electrophoresis
according to previously published methods [38]. The lG
and lA alleles were subsequently studied by enzymatic
digestion of 7 μl of the above mentioned PCR product
using 5 U of MspI and incubation at 37°C for a minimum
of 3 hours. The lG and lA alleles were then resolved on a
2% agarose gel. Because the lG and s alleles were shown to
be functionally equivalent, we derived three new geno-
type groups: s's' (lG lG, s lG, and ss), s'l' (lG lA and s lA) and l'l'
(lA lA).
Statistical analyses
Our primary outcome variables were CGI-Parents and
CGI-Teachers. The effects of genotype (s's', s'l' and l'l'),
gender, treatment (placebo and MPH), treatment order
and genotype by treatment interaction were tested using
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covariance matrix (SAS MIXED procedure, SAS version
6.12, SAS Institute Inc, Cary, NC) [39]. Treatment, order
of treatment, genotype, and treatment by genotype inter-
action were fixed effects; individuals were random
effects. The mixed model analysis of variance has many
advantages over repeated measures analysis of variance
[40]. Main effects and any interactions were regarded as
statistically significant when p < 0.05. Baseline value of
the outcome scores (CGI-Parents or CGI-Teachers rat-
ings) were respectively included as a covariate [41]. For
significant genotype by treatment interaction, simple
contrasts were carried out to explore how genotype and
treatment interact.
Demographic and clinical characteristics of the three 5-
HTTLPR genotype groups were compared using
ANOVA or χ2 tests as appropriate.
Results
The distribution of the 5-HTTLPR genotypes [ss (23%), sl
(45%), ll (32%)] did not depart from Hardy Weinberg pro-
portions (χ2 = 0.63, df = 2, p = 0.73). Similarly, s's' (27%),
s'l' (51%) and l'l' (22%) genotype distribution did not
depart from Hardy Weinberg proportions (χ2 = 0.62, df =
2, p = 0.73).
5-HTTLPR and clinical characteristics
Clinical characteristics of the three groups of children are
presented in Table 1. The distribution of the common
comorbid disorders of ADHD (oppositional defiant dis-
order, conduct disorder, anxiety disorders and mood dis-
orders) were similar among the three groups of children,
although anxiety disorders tended to be more frequent in
children with the s's' and, to a lesser extent, s'l' genotypes
compared to children with the l'l' genotype. However,
females were more represented in the group of children
with the s's' genotype (p = 0.008). Thus, we controlled for
gender in subsequent analyses.
Behavioral response to clinical intervention
A significant behavioral response during the week of
treatment with placebo, as assessed by comparing CGI
scores during the placebo week over baseline measures,
was observed for CGI-Parents (F1, 156 = 166, p < 0.001)
and CGI-Teachers (F1, 156 = 16.4, p < 0.001). This indicates
that the clinical intervention, irrespective of whether an
active drug or a placebo is delivered, resulted in a robust
behavioral response compared to the baseline levels as
assessed by both parents and teachers.
Effect of 5-HTTLPR on behavioral response to MPH
Mixed model analysis of variance with CGI-P scores as
the dependent variable, genotype as the independent
variable, and baseline scores and gender as the covariates
showed a significant genotype by treatment 2-way inter-
action [F2, 152 = 5.43, p = 0.005]. As depicted in Figure 1a,
behavioral response to MPH as compared to placebo was
significant for both the l'l' [F1, 33 = 5.3, p = 0.028] and s'l'
[F1, 80 = 23.9, p < 0.000] genotype groups. The s's' group
showed no significant response to treatment with MPH
[F1, 41 = 0.66, p = 0.42]. We also calculated the change
scores between the week of treatment with placebo and
the week of treatment with MPH. These scores were ana-
lyzed using univariate analysis of variance, which
revealed a significant genotype effect [F2, 154 = 6.0, p =
0.003]. Post hoc comparisons of the mean difference
scores using the Tukey's Honestly significant differences
(HSD) test revealed significant differences between the
s's' and s'l' (p = 0.002) and between the s's' and l'l' (p = 0.04)
genotype groups. There were no differences between s'l'
and l'l' genotype groups (p = 0.88). When we performed
similar analyses using a recessive model where the inde-
pendent between-subject variable was restricted to two
genotype categories (s's' vs. s'l'+l'l'), a highly significant
genotype effect was also observed (F1, 155 = 11.9, p =
0.0007). These results remained significant when we con-
trolled for anxiety disorders (p values < 0.05).
Similar analyses comparing baseline scores to placebo
also revealed a genotype effect [F2, 154 = 4.15, p = 0.02].
The s's' genotype group displayed a significant improve-
ment with placebo compared to the s'l' genotype group (p
= 0.02). No differences between s's' and l'l' or s'l' and l'l'
genotype groups were observed.
For the CGI-T scores, the mixed model analysis of vari-
ance revealed a highly significant treatment effect [F1, 152
= 31.0, p < 0.0001], no main effect of genotype [F2, 152 =
1.29, p = 0.28], nor a genotype by treatment interaction
[F2, 152 = 0.18, p = 0.83] (Figure 1b).
Effect of 5-HTTLPR on side effects induced by MPH
Side effects were collected in 105 patients both during the
week of treatment with MPH and the week of treatment
with placebo, using the Barkley Stimulant Drug Side
Effects Rating Scale [42], which delineates 17 side effects
commonly reported during treatment with stimulant
medications. Parents assessed the presence and severity
of these side effects, rating each item on a scale of 0
(absent) to 9 (severe). For each of these side effects, we
calculated the change score between the week of treat-
ment with placebo and the treatment with MPH. None of
the side effects was modulated by 5-HTTLPR genotype at
a Bonferroni corrected level of significance (0.003). All p-
values were higher than 0.15, except for the item "talks
less" (p = 0.03). In a post-hoc analysis (Tukey's HSD),
patients with the s's' genotype tended to talk less than
patients with the s'l' (p = 0.06) and patients with the l'l' (p
= 0.06) genotypes after treatment with MPH. There was
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change scores (r = -0.12, p = 0.19), indicating that this
item did not affect the parental rating of response to
MPH.
Interaction with the Dopamine transporter VNTR 
polymorphism
In order to investigate the interaction between the 3'-
UTR VNTR in the SLC6A3 gene and the 5-HTTLPR in
the SLC6A4 gene, we conducted an ANOVA where geno-
types in each of these two genes were the independent
factor and the change score in CGI-Parents was the
dependent outcome variable. This analysis resulted in a
significant effect of the 5-HTTLPR genotype (F2, 112 =
5.13, p = 0.007), a marginal effect of the DAT genotype
(F2, 112 = 2.35, p = 0.09) but no gene by gene interaction.
Table 1: Baseline characteristics of children with ADHD separated according to genotype in the triallelic 5-HTTLPR 
polymorphism of the SLC6A4 gene.
s's' genotype (n = 42) s'l' genotype (n = 81) l'l' genotype (n = 34) Statistic and p-value
Age 8.9 (1.80) 9.2 (1.90) 8.8 (1.70) F2,154 = 0.7, p = 0.52
Males/Females (% males) 30/12 (78%) 67/14 (88.5%) 34/0 (87.5%) χ2 = 11.2, df = 2, p = 0.003
Household income 
(% < $20,000 per year)
41.5% 31.6% 44.8% χ2= 1.9, df = 2, p = 0.38
Ethnic origin (Caucasian/non-Caucasian) 35/7 72/9 30/4 χ2 = 0.8, df = 2, p = 0.92
WISQ-III full scale IQ 96.9 (15.4) 99.3 (15.2) 97.3 (14.5) F2,144 = 0.4, p = 0.69
CBCL
Total score 69.4 (9.4) 69.5 (10.3) 70.4 (6.9) F2,149 = 0.1, p = 0.88
Internalizing problems 65.2 (11.8) 64.5 (12.3) 62.4 (8.6) F2,149 = 0.6, p = 0.54
Withdrawn 64.1 (11.7) 64.2 (10.7) 61.4 (7.6) F2,149 = 0.9, p = 0.41
Somatic complaints 61.3 (8.5) 59.3 (8.5) 56.9 (7.0) F2,149 = 2.4, p = 0.10
Anxiety/depression 65.1 (10.6) 66.3 (11.9) 63.0 (8.8) F2,149 = 1.1, p = 0.34
Social problems 65.8 (10.6) 67.6 (10.6) 68.0 (10.6) F2,149 = 0.5, p = 0.60
Thought problems 63.0 (11.1) 63.5 (10.8) 62.5 (9.5) F2,149 = 0.1, p = 0.88
Attention problems 70.3 (11.3) 70.5 (9.9) 68.3 (9.6) F2,149 = 0.6, p = 0.56
Externalizing problems 69.3 (9.5) 69.2 (11.4) 72.8 (7.6) F2,149 = 1.6, p = 0.21
Aggressive behavior 71.4 (11.9) 72.9 (13.6) 75.1 (9.7) F2,149 = 0.8, p = 0.46
Diagnosis C/I/H 21/16/5 42/30/9 25/5/4 χ2 = 6.6, df = 4, p = 0.15
Comorbidity (%) with
CD 28.5% 28.5% 30.5% χ2 = 0.03, df = 2, p = 1.0
ODD 38.0% 37.5% 42.5% χ2 = 0.2, df = 2, p = 0.88
AD 44.5% 28.0% 19.0% χ2 = 5.4, df = 2, p = 0.07
MD 16.7% 13.3% 3.8% χ2 = 2.4, df = 2, p = 0.30
Previously medicated (%) 51.3% 46.7% 48.4% χ2 = 0.22, df = 2, p = 0.90
Values are mean (SD) unless otherwise indicated. Demographic and clinical characteristics were compared between these groups using the 
appropriate statistic depending on the nature of the data. WISC = Wechsler Intelligence Scale for Children, 3rd edition; CBCL = Child Behavioral 
Checklist; C/I/H = Combined/Inattentive/Hyperactive; ODD = Oppositional Defiant Disorder, CD = Conduct Disorder, AD = Anxiety Disorder, MD 
= Major Mood Disorder. Number of observations varied some times with regard to variables (i.e. CBCL, WISC-III). Variation n number of 
observation is reflected in the degrees of freedom.
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Using MPH to probe behaviors in children with ADHD
may be a good approach to investigate relations between
genes and behaviors in this disorder. This approach has
the advantage of being supported by a wealth of informa-
tion on the molecular and neurochemical mechanisms of
MPH. The use of the double blind placebo-controlled
design is likely to refine the quality of the pharmaco-
behavioral genetic approach by controlling for bias in the
evaluation of behaviors. It is notable in this regard that
the only three studies using a double blind placebo-con-
trolled design to investigate behavioral response to
amphetamine in healthy volunteers [43] and MPH in
children with ADHD [5,6] found convergent results indi-
cating that subjects homozygous for the 9-repeat allele in
the 3'UTR VNTR polymorphism of the dopamine trans-
porter gene are less sensitive to the effects of psychostim-
ulants.
Based on the hypothesis of Gainetdinov and Caron
[8,9], that the paradoxical calming effects of MPH may be
due to enhanced 5-HT transmission downstream of the
dopamine system, it is possible that patients who are
homozygous for the s' allele, presumed to be impaired
with regard to 5-HT transmission, would present poor
response to MPH. In contrast, patients homozygous for
the l' allele, presumed to have more efficient 5-HT trans-
mission, would show very good response to MPH.
The main finding of this study is consistent with this
hypothesis to a certain extent. Indeed, we identified an
association between the triallelic 5-HTTLPR polymor-
phism in the 5-HTT gene and behavioral response to
MPH as assessed by the CGI- Parents. Children with the
s's' genotype responded significantly better to placebo and
did not derive a further improvement with MPH. On the
contrary, children with the l'l' genotype responded mini-
mally to placebo and derived significant improvement
with MPH. Children with the s'l' genotype had an inter-
mediate profile. The statistical differences are also
reflected in clinical differences. Indeed, children with the
l'l' genotype retained clinically significant impairment
after treatment with placebo (CGI-Parents>65) and
improved to the non-clinical range with MPH. In con-
trast, children with the s's' genotype showed significant
clinical improvement with placebo and appeared to dete-
riorate when MPH was added to their treatment.
Studies investigating the pharmacogenetics of ADHD
have reported both positive and negative results. Some
recent findings have detected no significant associations
between polymorphisms of the DAT1, DRD4 and 5-HTT
genes and response to MPH [44,45]. However, it has been
difficult to compare results from these studies given sig-
nificant variability in key methodological issues.
This current study design however is potentially more
robust given the placebo arm, which acts as an internal
control, quantitative measures of MPH response by two
raters, namely parents and teachers, as well as consider-
ation of comorbid disorders.
On the other hand, we did not identify a genotype or
genotype-by-treatment interaction with therapeutic
response to MPH as assessed by teachers in the school
environment. Although this apparently contradicts find-
ings from the parents' evaluation, this result could be
interpreted by the fact that environmental factors and
observer effects, as well as the interaction between the
observer and the child have an important impact on the
child's behavior and its assessment [46]. In fact, genetic
epidemiological studies suggest that the genetic factors
implicated in ADHD symptoms as evaluated by parents
Figure 1 CGI-P and CGI-T scores separated according to child's triallelic 5-HTTLPR genotype at three time points (B, P, and M). Conners' glob-
al index scores (± SD) for parents (1a) and teachers (1b) in children with ADHD separated according to their genotype in the 5-HTTLPR of the serotonin 
transporter gene (SLC6A4) during baseline evaluation (B), treatment with placebo (P) and treatment with methylphenidate (M). Dashed line represents 
the threshold for clinical significance on the Conners' scales (≥ 65). Asterisks indicate the levels of significance of the differences in CGI scores between 
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review by Thapar et al.[49]). Also, it has been demon-
strated that parent and teacher ratings of improvement
with MPH correlate only modestly [50] and differ in their
magnitude [33]. Faraone et al. reported that when poor or
no response is reported by one reporter (parents or
teachers), it is unlikely to be confirmed by the other [50].
Thus, it is possible that the 5-HTTLPR may be specifi-
cally modulating behaviors and therapeutic response of
these behaviors to MPH as evaluated by parents in the
home environment.
Also, it should be noted that the effect of the 5-
HTTLPR genotype remained significant after controlling
for the effect of the 3'UTR VNTR polymorphism of the
dopamine transporter gene, which was previously
reported to be associated with response to MPH [5,6].
However, these results need to be replicated in a larger
sample given that some genotype combinations were rep-
resented by few subjects.
Some limitations should be kept in mind while inter-
preting the results from this study. First, this study used a
single dose of MPH (0.5 mg/kg/day), which is in the low
to medium range commonly used in clinical practice. As
our primary purpose was to use MPH as a pharmacologi-
cal probe to challenge behaviors relevant for ADHD, we
used a dose that is both in the low/medium therapeutic
range and recommended as a starting dose. Even though
this dose elicited clinically and statistically significant
improvements, an experimental design with several doses
(including lower doses for some genotypes) and longer
periods of treatment with MPH treatment will be impor-
tant to further explore the clinical implications of the
present findings. Second, our sample comprised relatively
few females. Separate analyses on males and females
revealed essentially the same results in males but no sig-
nificant findings in females. A larger sample needs to be
studied in order to validate or refute these results in girls.
Furthermore, although the majority of subjects were
Caucasians, it is possible that differences in other loci
which are differentially distributed between the three
genotype groups could confound this finding. However,
there were no significant differences in the distribution of
Caucasians/non-Caucasians between the three genotype
groups.
Conclusion
In conclusion, this pharmacogenetic study investigating
the role of the 5-HTT gene in behavioral response to
MPH in children with ADHD is the largest study using
the double-blind, placebo-controlled, crossover design
for the evaluation of behavioral response to psychostimu-
lants. In addition, the assessment tools used in this study
were developed for children, have been standardized with
regard to the general population and were shown to be
adequate for the evaluation of therapeutic response to
drugs in children with ADHD. The results of this study
strongly suggest that children with the s's', s'l' and l'l' geno-
types may be characterized with differential profiles of
response to placebo and MPH in the context of a short
term clinical trial. If these profiles are confirmed in a
larger group of patients, this may help in the design of
better interventions that are tailored for the specific
needs of each of these groups of patients.
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